Objective To identify factors contributing to cognitive impairment in children with lupus nephritis. Study design A cross-sectional analysis of a large multicenter national cohort of children with chronic kidney disease (CKD) using standardized measures to determine baseline neuropsychiatric function and health-related quality of life (HRQoL) in children with lupus nephritis (n = 34), and to compare baseline function with that in children with other forms of glomerular CKD (gCKD; n = 171). We used inverse probability weighting via a logistic model for propensity score analysis to achieve balance between children with lupus nephritis and those with other glomerular causes of CKD, adjusting for known confounders. We used linear regression models to compare neurocognitive outcomes between exposure groups, adjusting for current prednisone use and testing for an interaction between current prednisone use and lupus nephritis, and to test for an association between cognitive function and HRQoL.
Results Current prednisone use was independently associated with worse attention (P < .01) and better adaptive skills (P = .04), and there was a significant interaction between current prednisone use and lupus nephritis for internalizing problems, with worse parent-reported internalizing problems in children with lupus nephritis on prednisone (P = .047). Better parent-reported HRQoL was associated with better visual memory (P = .01), and better child-reported HRQoL was associated with better attention (P < .01) and inhibitory control (P < .01). Both parent and child HRQoL were associated with better measures of executive function (P = .02 and < .001, respectively).
Conclusion Children with lupus nephritis have comparable or better cognitive function than their peers with other gCKDs, which is reassuring given the multiorgan and lifelong complications associated with lupus. (J Pediatr 2017;189:181-8).
C hildren with chronic kidney disease (CKD) are at risk for poor clinical and psychosocial outcomes because of kidney dysfunction, living with childhood chronic illness, and effects of treatments. Cognitive impairment in children with CKD is a known comorbidity, and studies indicate impaired function across several neurocognitive domains, including IQ, memory, and executive function. [1] [2] [3] Psychosocial functioning also may be adversely impacted in children with CKD, who suffer from higher rates of depressive and anxiety symptoms [4] [5] [6] [7] [8] and exhibit poorer health-related quality of life (HRQoL) compared with healthy peers. 9 Cognitive and behavioral dysfunction may adversely impact HRQoL, but little is known about this potential impact in children with CKD. Glomerular CKD (gCKD) may arise from several etiologies that may differentially impact cognitive and psychosocial functioning. Understanding these differences may yield insight into the pathophysiological mechanisms of cognitive and psychosocial dysfunction, as well as inform interventions to improve overall functioning and HRQoL in these children.
Fifty-five percent of children with systemic lupus erythematosus have gCKD, 10 and >20% exhibit moderate renal impairment by 10 years after diagnosis.
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Children with lupus nephritis also may have central nervous system (CNS) involvement, including neurocognitive impairment in up to 50%. [12] [13] [14] Inflammation of both the kidney and brain in children with lupus nephritis may exert concurrent adverse effects on cognitive and psychosocial function, and higher disease activity is associated with depression, anxiety, and poor HRQoL in these patients. 15, 16 In addition, management of lupus nephritis carries a high burden of immunosuppressive medication use 17 and of psychosocial stress due to uncertainty resulting from the episodic nature of lupus and the potential for stigmatizing skin lesions. [18] [19] [20] [21] Thus, children with lupus nephritis may have worse cognitive and psychosocial impairment than children with other forms of gCKD, but this has not been examined.
The Chronic Kidney Disease in Children (CKiD) prospective cohort study is a multicenter longitudinal investigation of children with mild-to-moderate CKD. 22 A primary goal of the CKiD study is to determine how a decline in kidney function affects neurocognitive function and behavior. As such, participants entered in CKiD undergo a battery of neurocognitive and behavioral tests, as well as repeated HRQoL assessments. Given the myriad of neuropsychiatric comorbidities associated with both CKD and lupus nephritis, we aimed to (1) determine whether children in the CKiD study with CKD secondary to lupus nephritis exhibit worse neurocognitive and psychosocial functioning and HRQoL compared with children with other forms of gCKD, and (2) examine the association of HRQoL with neurocognitive and behavioral functioning in children with lupus nephritis and other causes of gCKD.
Methods
The CKiD study's design and objectives have been described previously. 22 Inclusion criteria include age 1-16 years and an estimated glomerular filtration rate (eGFR) between 30 and 90 mL/min/1.73 m 2 . Exclusion criteria include renal or other solid organ, bone marrow, or stem cell transplantation, dialysis treatment within the past 3 months, HIV or cancer diagnosis or treatment within the past 12 months, structural heart disease, pregnancy within the past 12 months, genetic syndromes involving the CNS, and history of severe to profound intellectual disability. CKiD participants undergo standardized neurocognitive testing and assessment of psychosocial function at 6 months following study entry and then every 2 years after study entry. HRQoL is assessed at 6 months and at each annual visit thereafter. We used the baseline data (first visit with a measurement available) from these measures to determine the outcomes for this analysis. The CKiD study protocol was approved by the Institutional Review Boards at all participating sites, and informed consent and assent was obtained from all participants. 27 The WASI is a standardized measure of intelligence, and the WIAT-II-A is a standardized measure of academic achievement. Both tests are used for children aged ≥6 years and are reported as standardized scores with a mean of 100 and SD of 15; higher scores indicate better performance. The WISC-IV-I is a measure of intelligence that also measures discrete cognitive domains for children aged 6-16 years, with a mean of 10 and SD of 3; higher scores indicate better performance. The CPT-II measures attention, and the BRIEF is a parentcompleted inventory that measures executive function. They are both validated for children aged ≥6 years and have a mean score of 50 and SD of 10; lower scores indicate better performance. The D-KEFS is for children aged ≥8 years and also measures executive function, with a mean score of 10 and SD of 3; higher scores indicate better performance.
Neurocognitive and Psychosocial Outcomes
Psychosocial outcomes of interest were assessed with the Behavior Assessment of Childhood Disorders, Second Edition (BASC-2), both parent-and self-reports, 28 and the PedsQL 4.0 HRQoL survey. 29 Both versions of the BASC-2 yield a total Behavioral Symptom Index Score and scores for the Externalizing Problems, Internalizing Problems, and Adaptive Skills indices. In addition, the child report yields the School Problems score. All scores on the BASC-2 have a mean of 50 and SD of 10. A higher score indicates better adaptive skills, and a lower score indicates worse behavioral symptoms, externalizing problems, internalizing problems, and school problems. HRQoL was assessed by the parent and self-report of the PedsQL 4.0. Domains of physical, emotional, social, school, and overall were measured. HRQoL scores range from 0 to 100, with higher scores indicating better HRQoL.
Statistical Analyses
The primary outcomes of interest were the neurocognitive measures and BASC-2 and HRQoL scores. Descriptive statistics for the demographic, neurocognitive, BASC-2, and HRQoL variables were generated to characterize the study sample. For examination of differences in neurocognitive and psychosocial outcomes by disease group, the categorical exposure was lupus nephritis vs other gCKDs. To balance covariates between groups, we derived propensity scores from a logistic regression model containing the following variables: age, sex, height Z-score, race, ethnicity, maternal education, eGFR, 30 urine protein/creatinine ratio, systolic blood pressure Z-score, and anemia status. These variables were selected a priori to be likely risk factors and confounders for the outcomes. Three participants with unknown ethnicity were imputed as non-Hispanic based on the demographics of the sample. Inverse probability weighting based on the propensity score was used to adjust for exposure group differences within regression models. Weights were winsorized at the 1st and 99th percentiles for stability. Linear regression analyses were used to determine the differences in neurocognitive and psychosocial outcomes between the children with lupus nephritis and those with other gCKDs. Median regression was used to determine differences in HRQoL outcomes. Current prednisone use (yes/no) was included as a covariate and potential effect modifier.
To examine the relationship of HRQoL to the neurocognitive and psychosocial outcomes, we used a nonweighted linear regression model to assess the effect of a 10-point increase in HRQoL on the outcomes. Covariates included maternal education, eGFR, urine protein/creatinine ratio, and systolic blood pressure Z-score. Lupus nephritis status was included as a covariate and potential effect modifier. Inverse probability weights were not used for this analysis, because the primary interest was in the effect of HRQoL, which was assumed to be equal in the children with lupus nephritis and those with other gCKDs unless the interaction indicated otherwise.
We performed a sensitivity analysis comparing the lupus nephritis group with a subgroup of participants with other gCKDs that excluded those with the following systemic vascular glomerular diseases: chronic glomerulonephritis (n = 16), Henoch-Schonlein nephritis (n = 9), and idiopathic crescentic glomerulonephritis (n = 7). This was done to determine whether our findings may be related to overall systemic inflammation as opposed to specific effects of lupus nephritis.
All P values were 2-sided, at a significance level of .05. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina). No adjustment was made for multiple comparisons.
Results
We identified 34 participants with lupus nephritis and 171 participants with other gCKDs with baseline data for the inverse probability-weighted analysis. The specific diagnoses included in the other gCKD group are listed in Table I (available at www.jpeds.com). Compared with participants with other gCKDs, those with lupus nephritis had a shorter median duration of CKD (1.6 vs 4.0 years) and a higher rate of prednisone use (59% vs 23%). Additional demographic and disease characteristics are presented in Table II .
Neurocognitive Outcomes
In adjusted analyses, compared with the other gCKD group, the lupus nephritis group had better performance for attention on the CPT-II Detectability test (b = −7.41; P < .01) and better executive function on the D-KEFS Achievement test (b = 1.66; P = .03) ( Table III) . There were no differences for the other cognitive measures, and no significant interactions between current prednisone use and lupus nephritis. Current prednisone use was independently associated with worse attention on the CPT-II Detectability test (b = 4.48; P = .01) and showed a significant association with better achievement on the WIAT-II-A (b = 8.62; P = .05).
Psychosocial Outcomes
In adjusted analyses, there were no statistically significant differences between the lupus nephritis and other gCKD groups in overall behavioral symptoms, externalizing problems, internalizing problems, adaptive skills, or school problems on the parent-reported BASC-2 (Table IV) . Current prednisone use was independently associated with better adaptive skills (b = 3.43; P = .04). There was a statistically significant interaction indicating worse parent-reported internalizing problems BP, systolic blood pressure; P/C, protein:creatinine. Shown are the demographic and disease variables characterizing the unweighted and inverse-probability-weighted samples of patients with lupus nephritis and other gCKDs.
in the children with lupus nephritis receiving prednisone (b = 10.18; P = .047). There were no significant differences between the lupus nephritis and other gCKD groups in parentor child-reported HRQoL measures.
Association of Neurocognitive Outcomes with HRQoL
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Volume 189 function on the BRIEF with an equivalent parent-reported HRQoL score (b = −2.47; P = .03). There were no statistically significant interactions between child-reported HRQoL and lupus nephritis for the neurocognitive outcomes.
Association of Psychosocial Outcomes with HRQoL
Better parent-reported overall HRQoL was associated with less parent-reported overall behavioral symptoms (b = −2.93; P < .001), externalizing problems (b = −1.58; P < .001), and internalizing problems (b = −3.44; P < .001) and better adaptive skills (b = 2.10; P < .001). Better parent-reported HRQoL also was associated with fewer child-reported school problems (b = −1.99; P < .01) and internalizing problems (b = −1.46; P < .0) (Figure) . Better child-reported overall HRQoL was associated with less parent-reported overall behavioral symptoms (b = −2.14; P < .001), internalizing problems (b = −3.63; P < .001), and adaptive skills (b = 1.50; P < .01) and fewer child-reported internalizing problems (b = −2.36; P < .001). There were no significant interactions between HRQoL and lupus nephritis for the psychosocial outcomes.
Sensitivity Analysis
In sensitivity analyses, compared with the gCKD (n = 139), the lupus nephritis group (n = 34) had higher intelligence scores on the WASI (b = 9.43; P = .03), higher executive function scores on the D-KEFS Achievement test (b = 1.56; P = .03), and better performance for attention/inhibitory control on the CPT-II Errors of Commission test (b = −5.86; P < .001) and Detectability test (b = −7.97; P = .02). There were no between-group differences for the other cognitive measures, and there were no significant interactions between current prednisone use and lupus nephritis. Current prednisone use was independently associated with better parent ratings of global executive function on the BRIEF (b = −4.12; P = .05), but worse inhibitory control and attention regulation on the CPT-II Errors of Commission test (b = 4.70; P = .04) and Detectability test (b = 5.52; P = .008). Sensitivity analyses showed no statistically significant differences between the lupus nephritis and other gCKD groups in terms of psychosocial measures. Current prednisone use was not independently associated with the psychosocial measures; however, there was a statistically significant interaction indicating worse parent-reported internalizing problems in children with lupus nephritis on prednisone (b = 13.64; P = .004). There were no statistically significant differences in the HRQoL measures between the lupus nephritis and other gCKD groups. Current prednisone use was independently associated with decreased child-reported overall HRQoL (b = −7.00; P = .04). Results of the sensitivity analysis did not differ for the associations of HRQoL with the neurocognitive or psychosocial outcomes, except for a statistically significant interaction indicating fewer parent-reported internalizing symptoms in the lupus nephritis group compared with the other gCKD group with an equivalent parent-reported HRQoL score (b = 2.54; P = .02).
Discussion
Although children with gCKD are known to be at risk for poor cognitive and psychosocial outcomes, there has been little study of potentially important differences among children with different etiologies of gCKD. This analysis provides results from a cross-sectional study of a large prospective cohort of children with CKD that showed comparable or better cognitive and psychosocial functioning in children with lupus nephritis compared with those with other causes of gCKD. Our study also provides new insight into the relationship between HRQoL and specific domains of cognitive and psychosocial function in this population. Our findings may begin to inform differences in pathophysiology and intervention targets.
Contrary to our hypothesis, we found that neurocognitive outcomes in children with lupus nephritis were the same as or better than those of their counterparts with other causes of gCKD. Although we found differences in attention/inhibitory control (CPT-II Detectability test) and executive function (D-KEFS Achievement test) between the groups, they were quite subtle, approximating 0.5 SD in standardized T-score. Nevertheless, these findings held in our sensitivity analyses, which also indicated higher scores for intelligence and CPT-II Errors of Commission in the children with lupus nephritis. One explanation for our findings may be that children with lupus nephritis have a shorter disease duration compared with children with other causes of gCKD, resulting in less cumulative CNS effects and a lower psychosocial burden due to CKD. It is possible that over time, children with lupus nephritis may experience deteriorating cognitive functioning, although the difference between groups may persist. In addition, there may be a worse developmental impact due to the presence of a neurocognitive insult at an earlier age in children with other causes of gCKD compared with children with lupus nephritis, although this hypothesis has not been demonstrated in other CKiD studies. 1, 31 A third possible explanation is that children with lupus nephritis experience less CNS effects than children with other causes of gCKD due to greater use of immunosuppression, such as prednisone and other chemotherapeutic agents. In our cohort, prednisone use was greater in the lupus nephritis group and was independently associated with better executive function in sensitivity analyses; however, this effect was not present across cognitive domains, prednisone was associated with worse attention, and we had no data on past prednisone exposure. Finally, it is possible that the pathophysiology of lupus nephritis may portend less brain inflammation, given that lupus has heterogeneous clinical manifestations and likely heterogeneous pathophysiology. Counter to this theory, a post hoc analysis revealed that a history of seizures was more common in the lupus nephritis group (21% vs 13%).
Our study did not find differences in the psychosocial functioning of children with lupus nephritis compared with children with other causes of gCKD. Behavioral and HRQoL outcomes were similar in the 2 groups, despite the multiorgan effects of systemic lupus erythematosus and the higher burden of systemic medications in the lupus nephritis group. More than 70% of the children in the lupus nephritis group were being treated with corticosteroids, compared with 30% in the other gCKD group. This suggests that the reason for the similar performance is not similar disease treatment effects, and that despite intense treatment, children with lupus nephritis are maintaining appropriate psychosocial functioning and are not experiencing detriments to their quality of life. It is also possible that because most children with lupus nephritis are seen by caregivers from at least 2 subspecialties (nephrology and rheumatology), they are better supported from both a medical and psychosocial standpoint, allowing them to maintain a high level of functioning despite the challenges of living with a complex chronic disease.
Interestingly, we found associations between HRQoL and the domains of cognitive and psychosocial functioning. For cognitive outcomes, lower parent-reported HRQoL was associated with worse visual memory, but lower child-reported HRQoL was associated with worse executive function, including attention regulation and inhibitory control. For psychosocial symptoms, unsurprisingly, worse overall symptoms were associated with worse parent-and child-reported HRQoL, but only child-reported internalizing problems and adaptive skills were associated with worse HRQoL. These results support previous findings of differences between child-reported and parentreported HRQoL, 32 showing the different information obtained from the different perspectives. Our findings also indicate that factors affecting parent-reported HRQoL may differ among different gCKD etiologies. For similar parent-reported HRQoL, parents of the lupus nephritis group reported worse executive function but fewer internalizing problems and less adaptive dysfunction compared with parents of the other gCKD group. These findings merit further study given their implications for addressing HRQoL for different forms of CKD.
Our study has several limitations. First, the small sample size reduces our ability to detect small differences between the lupus nephritis and other gCKD groups. This is of particular concern in our attempts to determine the extent to which corticosteroid treatment may be either mitigating or exacerbating the effects of disease on functioning. Second, the study's crosssectional design precludes the generation of conclusions about causality regarding associations between HRQoL and cognitive and psychosocial functioning. Third, although we adjusted for the duration of CKD, we were unable to adjust for the duration of the disease causing CKD, which may be longer for those with lupus nephritis and contribute to worse cognitive and psychosocial functioning in this group. However, we would not expect this to significantly impact our results, given that lupus nephritis is present within 1 year of diagnosis in 85% of patients. 10 Fourth, there may be selection bias if the children participating in CKiD are more likely to have better cognitive and psychosocial functioning than those choosing not to participate. However, we would expect this to be a nondifferential bias affecting generalizability, but not our comparison of lupus nephritis and other gCKDs. Finally, our results are from children with a median eGFR of~60 mL/min/ 1.73 m 2 and might not be generalizable to children with poorer kidney function, who may have worse cognitive and psychosocial outcomes. 1, 33 Finally, when developing weights for our propensity scores, we used all 205 subjects. Because not all subjects are included in each model, these weights might not be valid if the missingness in the outcome is not independent of covariates in the weighting model. ■ Table I . Diagnoses of children with other gCKDs (n = 171) 
